Stay updated with breaking news from Agvhd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Nelson J. Chao, MD, MBA, presents the patient profile of a 60-year-old man with chronic myeloid leukemia and graft-versus-host disease (GVHD) and shares his initial impressions.
The high dividend ETF duo of DIVI and UDIV could present an opportunity for agile current income as interest rate hikes loom.
Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal (GI) aGvHD-free survival by Day 180 after allo-HSCT with no relevant differences in safety profile versus placebo.1
Top low-vol ETF stories of 2022 focused not only on low-vol strats, but also a standout theme in dividends, which may intrigue investors.
RGI-2001 was well tolerated and associated with a meaningful reduction in the incidence of severe acute GvHD REGiMMUNE Limited, a clinical-stage biopharmaceutical company developing innovative